ANRO — Alto Neuroscience Share Price
Last trade - 00:00- $63.62m
- -$93.05m
- 45
- 50
- 24
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.42 | ||
| Price to Tang. Book | 0.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.95% | ||
| Return on Equity | -55.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.21 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. The advanced programs are supported by prospectively replicated evidence of clinical activity in biomarker-characterized populations.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 25th, 2019
- Public Since
- February 2nd, 2024
- No. of Shareholders
- 30
- No. of Employees
- 76
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 27,072,129
- Address
- 650 Castro Street, Suite 450, MOUNTAIN VIEW, 94041
- Web
- https://www.altoneuroscience.com/
- Phone
- +1 7732555012
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ANRO
Similar to ANRO
ADC Therapeutics SA
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Aurion Biotech
New York Stock Exchange
Biohaven
New York Stock Exchange
FAQ
As of Today at 01:12 UTC, shares in Alto Neuroscience are trading at $2.35. This share price information is delayed by 15 minutes.
Shares in Alto Neuroscience last closed at $2.35 and the price had moved by -83.37% over the past 365 days. In terms of relative price strength the Alto Neuroscience share price has underperformed the S&P500 Index by -84.65% over the past year.
The overall consensus recommendation for Alto Neuroscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAlto Neuroscience does not currently pay a dividend.
Alto Neuroscience does not currently pay a dividend.
Alto Neuroscience does not currently pay a dividend.
To buy shares in Alto Neuroscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.35, shares in Alto Neuroscience had a market capitalisation of $63.62m.
Here are the trading details for Alto Neuroscience:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ANRO
Based on an overall assessment of its quality, value and momentum Alto Neuroscience is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alto Neuroscience is $11.50. That is 389.36% above the last closing price of $2.35.
Analysts covering Alto Neuroscience currently have a consensus Earnings Per Share (EPS) forecast of -$2.67 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alto Neuroscience. Over the past six months, its share price has underperformed the S&P500 Index by -43.32%.
As of the last closing price of $2.35, shares in Alto Neuroscience were trading -65.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alto Neuroscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Alto Neuroscience's directors